Tokyo-based global pharmaceutical giant, Daiichi Sankyo has strengthened its position in Latin America by creating completely owned subsidiaries in Mexico and Colombia. These subsidiaries, Daiichi Sankyo Mexico, Sociedad Anonima de Capital Variable, and Daiichi Sankyo Colombia, Sociedad por Acciones Simplificadas, will support the company's expansion in the region by developing, selling, and marketing pharmaceutical products.

Both subsidiaries have a clear and structured capital ownership mechanism. Daiichi Sankyo Co., Ltd. owns 49,999 shares of Daiichi Sankyo Mexico, while Daiichi Sankyo Business Association owns one stock. This structure ensures that Daiichi Sankyo retains complete control of its Mexican businesses.

Similarly, Daiichi Sankyo Colombia is a Sociedad por Acciones Simplificadas. The capital structure is similar to that of its Mexican equivalent, with Daiichi Sankyo Co., Ltd. owning 49,999 stocks and Daiichi Sankyo Business Associates owning one share. Daiichi Sankyo also owns the Colombian subsidiary outright, giving the parent corporation complete ownership and control over its operations in Colombia.

These companies were created to demonstrate the strategic importance of the Latin American market to Daiichi Sankyo's global operations. The company's focus on the region is consistent with its overall strategy of broadening its worldwide reach and boosting market share in important emerging countries. Daiichi Sankyo hopes that having direct management over operations in Mexico and Colombia will allow it to better serve these countries' healthcare needs. making its innovative pharmaceutical goods more accessible to patients.

Daiichi Sankyo's expansion into Mexico and Colombia comes at a time when the company has posted outstanding financial results in many global markets. Daiichi Sankyo's FY2020 consolidated financial figures showed revenue of ¥962.5 billion. Despite strong product success, like Tarlige, their Japan business revenue decreased by ¥49.4 billion. Factors such as the influence of generic medications on Memary sales, the termination of vaccine business relationships and lower Inavir sales due to a lesser flu season were responsible for this decrease.

However, the corporation had positive growth in other locations. Daiichi Sankyo, Inc.'s revenue in the US increased by ¥16.5 billion, mostly due to the successful introduction of Enhertu in January 2020. In Europe, Daiichi Sankyo Europe GmbH witnessed a revenue increase of ¥13.6 billion, mostly due to increasing Lixiana sales, although there was a decline in olmesartan sales.

The Asia, South and Central America (ASCA) area, which includes Mexico and Colombia, also increased Daiichi Sankyo's overall income. The area recorded a year-on-year revenue gain of ¥4.7 billion, mostly due to increasing edoxaban sales. This increase in ASCA highlights the potential for additional growth and success in the Latin American market, which Daiichi Sankyo is now better at positioned to capitalise on via its wholly owned subsidiaries.

Daiichi Sankyo Mexico and Daiichi Sankyo Colombia, with their robust capital structures and clear ownership, are well-positioned to contribute significantly to the company's overall growth strategy. The formation of these companies represents a significant step forward in Daiichi Sankyo's ambitions to expand its footprint in emerging countries and reinforce its worldwide pharmaceutical leadership position.